TITLE

Fast-rising generics producer breaks ice in the US via merger

AUTHOR(S)
Jarvis, Lisa
PUB. DATE
May 2005
SOURCE
Chemical Market Reporter;5/30/2005, Vol. 267 Issue 22, p35
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that Actavis Group based in Reykjavik, Iceland, has improved its financial performance by making good on a long-standing goal of penetrating the U.S. market in the generic pharmaceuticals arena. Total revenue of the company in 2004; Number of products sold in the U.S. market for cardiovascular and central nervous system drug; Increase of sales in 2005.
ACCESSION #
17191092

 

Related Articles

  • Full steam ahead for Actavis in generics.  // Chemical Market Reporter;7/17/2006, Vol. 270 Issue 2, p24 

    The article announces that Iceland-based Actavis is pushing through with its generic pharmaceuticals business in its attempt to attain a leading position in the worldwide generic drug industry. Actavis now sells dantrolene and isradipine in the United States. It also markets amantadine,...

  • Actavis to Build Three Plants in India; Opens Laboratories. Ramesh, Deepti // Chemical Week;11/3/2008, Vol. 170 Issue 34, p31 

    The article reports on the announcement by generics pharmaceutical manufacturer Actavis that it is building three pharmaceutical plants in India. It broke ground on a pilot plant and an active pharmaceutical ingredient (API) plant at the company's existing API facility at Alathur, in southern...

  • Actavis Expands into New Markets; May Enter Biosimilars. Ramesh, Deepti // Chemical Week;10/26/2009, Vol. 171 Issue 26, p31 

    The article reports on the decision of generic pharmaceuticals producer Actavis to expand its operations in other regions. According to Stefan Sveinsson, executive vice president of Actavis, the company is planning to enter the biosimilars market through joint ventures and partnerships....

  • Generics: heading toward consolidation? Polastro, Enrico; Tulcinsky, Sonia; Boswell, Clay // ICIS Chemical Business Americas;10/2/2006, Vol. 270 Issue 12, p26 

    The article reports on the booming generic drugs industry. A number of factors attribute to the growth in the generic drugs which include the expiration of major drugs expected over the period of 2006-2012. The $65bn generics global market account for nearly 12% of the total pharmaceuticals...

  • Established Presence.  // Retail Merchandiser;Nov/Dec2009, Vol. 49 Issue 6, p128 

    The article explores how Actavis Group, a generic pharmaceutical manufacturer successfully entered the U.S. market and established Actavis Inc. The company is ranked fifth in terms of size among the world's generic pharmaceutical manufacturers. It relates how Actavis' acquisitions of Amide...

  • Shoddy production. Collier, Roger // CMAJ: Canadian Medical Association Journal;3/4/2009 Doctor's Health Matters, Vol. 180, p505 

    The article reports on the approval of the United States Food and Drug Administration (FDA) to let the pharmaceutical firm Actavis Inc. resume its operations only if it meets the Good Manufacturing Practice standards set by FDA. It states that the company was closed because of shoddy production...

  • Firms battle over Merck. Williams, Dede // ICIS Chemical Business;2/19/2007, Vol. 2 Issue 54, p9 

    The article focuses on the companies bidding for Merck Generics. India's Ranbaxy is bidding for Merck together with Kohlberg, Kravits, Roberts. Actavis has confirmed that it is interested in buying Merck. Other bidders include Texas Pacific, Bain Capital, Blackstone, Permira and EQT. Merck KGaA...

  • Depression Update.  // PharmaWatch: CNS;Sep2010, Vol. 9 Issue 9, p10 

    The article offers news briefs on depression in the U.S. The Food and Drug Administration (FDA) has allowed Actavis Inc., a subsidiary of generic pharmaceutical company Actavis Group hf, to market Bupropion HCI extended-release (SR) tablets 100 milligram (mg) and 200 mg for the treatment of...

  • pharmaceuticals & fine chemicals.  // Chemical Week;10/26/2005, Vol. 167 Issue 35, p34 

    Presents an update on the pharmaceutical industry as of October 26, 2005. Purchase of the generic drugs operations of Alpharma by generic drugs firm Actavis Group; Decision of biotechnology manufacturer Progenitor Cell Therapy to manufacture Cellerant Therapeutics' stem cell drug candidate CLT-001.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics